查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138265

2022-2029 年宏基因组测序全球市场

Global Metagenomic Sequencing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球宏基因组测序市场的增长受到某些因素的推动，例如先进的技术平台、改进的基因组工具，以及政府和私人组织对大型测序项目的承诺和资金增加。它是主要的基因组测序市场之一。市场增长的因素。

在预测期内，先进的技术平台和改进的基因组工具有望推动全球宏基因组测序市场。

推动宏基因组测序市场增长的主要因素之一是更快的测序技术的持续发展以及处理产生的海量数据的各种方法的进步，这导致了研究人员无穷无尽的能力分析来自各种环境的微生物群落正在扩大。

越来越多地采用具有成本效益的技术开发，例如先进的生物信息学工具、高通量筛选 (HTS) 方法、药物回收和下一代测序 (NGS)，正在推动市场增长。下一代 DNA 测序 (NGS) 技术的发展推动了分子生物学研究，带来了多项发现和新见解。下一代 DNA 测序技术超越了历史悠久的 DNA 测序，其应用超出了分子生物学的原理。

2019年5月28日，精准医疗生物技术公司Macrogen被韩国食品药品安全部（MFDS）指定为临床试验标本分析实验室。该认证将改善临床诊断宏基因组学并使 Macrogen 受益。

因此，预计 DNA 测序技术的不断进步将在预测期内推动市场增长。

政府和私人组织加大对大型测序项目的投入和资金投入

人们对遗传病的认识不断提高，政府加大对大型测序项目的承诺和资金投入是推动全球宏基因组测序市场增长的主要因素。例如，2019 年，QIAGEN 与多家英国组织建立了合作伙伴关係，以支持并在英国曼彻斯特建立一个全球基因组学园区。新的基因组健康创新园区将致力于生命科学、转化科学和分子诊断领域的创新。

2019年11月，“人类百万微生物组计划”（MMHP）在第十四届国际基因组学会议（ICG-14）上正式启动。来自中国、法国、瑞典、丹麦、拉脱维亚等国的科学家将合作开展微生物宏基因组研究，未来3-5年，对肠道、皮肤、口腔、生殖道等100万份微生物样本进行测序分析。我们的目标是绘製人体微生物组图，建立全球最大的人体微生物组数据库。

阻碍宏基因组测序市场增长的因素

但是，也存在一些挑战，例如对诊断测试的标准化和准确性的担忧日益增加、对各种分离和鑑定技术的并行发展的需求、更高效和强大的生物资讯学工具以及熟练专业人员的短缺。阻碍市场增长。

细分分析

在预测期间（2022-2029 年），鸟枪法宏基因组测序技术领域预计将以最快的复合年增长率增长。

宏基因组测序市场按技术分为 16S rRNA 测序、鸟枪法宏基因组测序、全基因组测序和从头组装以及宏转录组学。在这些细分市场中，研究人员和医疗保健专业人员越来越多地采用鸟枪法宏基因组测序，鸟枪法测序提供了优于其他技术的一些优势，并且基于宏基因组测序的鸟枪法宏基因组测序技术在预测期内以最快的速度增长，部分原因是以增加研究活动。鸟枪法测序可以检测微生物群落的低丰度成员。与全基因组测序相比，鸟枪法宏基因组测序可以针对环境样本中发现的所有生物的所有基因，并且可以针对仅一种生物的所有基因。

全球宏基因组测序市场报告提供对大约 40 多个市场数据表、45 多个图表和 180 页的访问。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品/服务划分的市场细分
  • 按技术划分的市场细分
  • 按工作流程划分的市场细分
  • 按应用划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 促进因素
    • 加大对大型测序项目的投入和资金投入
    • 宏基因组学在各个领域的大应用
  • 抑制因素
    • 新兴国家的预算限制
    • 缺乏熟练的专业人员
  • 商机
    • 用于数据管理的云计算的兴起
  • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 临床试验
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品/服务分类

  • 仪器
  • 试剂和耗材
  • 分析和数据分析解决方案
  • 服务
  • 其他

第 8 章按工作流程

  • 数据处理和分析
  • 样品製备和库创建
  • 测序

第 9 章技术

  • Shotgun 宏基因组测序
  • 16S rRNA测序
  • 全基因组测序和从头组装
  • 元转录组学

第 10 章按应用程序

  • 药物发现
  • 临床诊断
  • 动物用药
  • 在生态环境领域的应用
  • 工业领域的应用
  • 土壤微生物组应用
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 13 章公司简介

  • Thermo Fisher Scientific Inc.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Qiagen N.V.
  • BGI Group
  • DNAstar, Inc.
  • Eurofins Scientific
  • Illumina, Inc.
  • Macrogen, Inc.
  • Oxford Nanopore Technologies Ltd.
  • NuGEN Technologies, Inc.（A Wholly Owned Subsidiary of Tecan Trading AG）
  • F. Hoffmann-La Roche Ltd.
  • Perkinelmer, Inc.
  • Integragen SA
  • Microsynth AG
  • Novogene Co., Ltd.
  • Zymo Research Corporation（List Not Exhaustive）

第 14 章数据M

简介目录
Product Code: DMBT2643

Market Overview

Metagenomic Sequencing Market is expected to grow at a CAGR of 19.3% during the forecasting period (2022 - 2029). Metagenomics is a research field where genomic analysis of microbial DNA from environmental communities is studied. Metagenomic sequencing techniques enable scientists to analyze genes in a given sample. The method allows researchers to assess bacterial diversity and identify the presence of microbes in various environments. Steps involved in metagenomics sequencing include DNA extraction, library preparation, sequencing, assembly, annotation, and statistical analysis.

The Metagenomic Sequencing market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Metagenomic Sequencing segmentation by product & service, workflow, and application. It also provides metagenomic sequencing market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global metagenomic sequencing market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global metagenomic sequencing market growth driven by certain factors such as advanced technological platforms and improved genomic tools, increasing initiatives and funds by government and private organizations to large scale projects of sequencing are among the key factors driving the market growth.

Advanced technological platforms and improved genomic tools, is expected to drive the global metagenomic sequencing market during the forecast period;

One of the major factors driving the growth of the metagenomic sequencing market is the continuous development of faster sequencing techniques and advancements in different methods to cope with the huge data generated, which are expanding researchers' capacity to analyze microbial communities from an unlimited variety of environments.

The growing adoption of advanced bioinformatics tools, high throughput screening (HTS) methods, recovery of novel drugs, and development of cost-effective technologies such as next-generation sequencing (NGS) are driving the market growth. The development of Next Generation DNA Sequencing (NGS) technology has driven molecular biology research, leading to several discoveries and new insights. Next-generation DNA sequencing technology goes beyond long-established DNA sequencing with its applications that reach across the principles of molecular biology.

On May 28, 2019, a precision medicine biotechnology company, Macrogen, Inc. received South Korean accreditation of Good Clinical Lab Practices from the country's Ministry of Food and Drug Safety (MFDS) and designated as a clinical trial specimen analysis institution. It would benefit Macrogen with improvised clinical diagnostic metagenomics.

Hence, increasing technological advancements regarding DNA sequencing is expected to drive market growth over the forecast period.

Increasing initiatives and funds by government and private organizations to large scale projects of sequencing

The growing awareness of genetic disorders and increasing government initiatives and funds for large-scale projects of sequencing are among the major factor driving the growth of the global metagenomic sequencing market. For instance, in 2019, QIAGEN got into a partnership with multiple organizations in the UK to support and establish its global genomics campus in Manchester (UK). The new Genomic Health Innovation Campus will aim at innovation in life sciences, translational sciences, and the molecular diagnostics field.

Also, in November 2019, The "Million Microbiome of Humans Project" (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, France, Sweden, Denmark, Latvia, and other countries will cooperate in microbial metagenomic research, aiming to sequence and analyze one million microbial samples from intestines, skin, mouth, reproductive tract, and other organs in the next 3-5 years to draw a microbiome map of the human body and build the world's largest database of the human microbiome.

Factors hampering the growth of the metagenomic sequencing market

However, the market growth is hampered by several factors such as growing concerns towards the standardization and accuracy of diagnostic testing, its requirement for parallel advancement in various isolation and identification techniques, more efficient & robust bioinformatics tools, and lack of skilled professionals.

Segmentation Analysis

The shotgun metagenomic sequencing technology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

By technology, the metagenomic sequencing market is segmented into 16S rRNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing & de-novo assembly, and metatranscriptomics. Out of all these segments, the shotgun metagenomic sequencing technology is growing at the fastest growth rate over the forecast period, due to the growing adoption of shotgun metagenomic sequencing among researchers and healthcare professionals, several advantages offered by shotgun sequencing compared with other techniques, and the increasing number of metagenomic sequencing-based research activities. Shotgun sequencing can detect low abundance members of microbial communities. Shotgun metagenome sequencing can target all genes from all organisms found in an environmental sample, in contrast to the whole sequencing and targeting all genes from only one organism.

Geographical Analysis

North America region holds the largest market share of the global Metagenomic Sequencing market

North America region is dominating the global metagenomic sequencing market accounted for the largest market share in 2019, owing to technological advancements in the next-generation sequencing procedures along with its increasing applications, favorable initiatives by government and private bodies for the development and adoption of NGS-based metagenomics technologies, the wide adoption of metagenomic diagnostics in the region, and rising awareness of metagenomics sequencing services. The market players are collaborating to introduce new procedures with innovative technology. For instance, In 2019, Illumina and Thermo Fisher Scientific (U.S.) entered into a commercial agreement for the sales of Thermo Fisher's Ion AmpliSeq technology to researchers who use Illumina's NGS platforms.

Competitive Landscape

The metagenomic sequencing market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., BGI Group, DNAstar, Inc., Eurofins Scientific, Macrogen, Inc., Oxford Nanopore Technologies Ltd., Brooks Automation, Inc. (GENEWIZ), Perkinelmer, Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the metagenomic sequencing market globally. For instance,

In 2019, Illumina acquired Pacific Biosciences, one of the leading providers of sequencing systems. This helped Illumina strengthen its sequencing product portfolio.

In 2019, Illumina acquired Edico Genome, a software provider for NGS.

In 2019, Microba had partnered with Macrogen to develop microbiome research services for international markets.

In 2019, Eurofins Scientific acquired TestAmerica, a leading environmental testing laboratory group in the US. This helped Eurofins strengthen its presence in the US market.

In November 2018, Brooks Automation, Inc. acquired the GENEWIZ group which will improve the company's global services of metagenomics sequencing.

In 2017, QIAGEN acquired Microsoft Corporation (US), management, visualization, and analysis software provider for bioinformatics, NGS, and cancer genomics.

COVID-19 Impact Analysis

The metagenomic sequencing market is positively impacted by COVID-19 as, throughout the COVID-19 pandemic, testing is a critical component of the response and rapidly increasing, which enables rapid identification and isolation of infected individuals. The Majority of this testing is PCR-based, detecting the presence of the SARS-CoV-2 virus only.

Next-generation sequencing (NGS) of the COVID-19 virus is providing powerful metagenomic data, that is combined with clinical data to search for effective treatments. Continous genomic and epigenomic analysis of SARS-CoV-2 is critical, used to determine the number of virus strains, how the virus is spread into new regions, number of introductions of the virus if there is community spread of the virus if outbreaks are linked, and how the virus is evolving.

Oxford Nanopore Technologies is doing the Metagenomic analysis of SARS-CoV-2 respiratory samples via Sequence-Independent Single Primer Amplification (SISPA) and nanopore sequencing.

Industry Analysis

The global metagenomic sequencing market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, clinical trials, pricing analysis etc, unmet needs, reimbursement analysis.

Key Companies to Watch

Illumina, Inc

Overview: Illumina, Inc. was incorporated in April 1998, and headquarter located in San Diego, California. The company develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serve the sequencing, genotyping and gene expression, and proteomics markets.

Product Portfolio: The company's product portfolio includes a wide range of highly interconnected products, including sequencing, genotyping, gene expression, and molecular diagnostic products. Illumina also offers metagenomic sequencing services, which further strengthens its market position.

Key Development: In 2019, Illumina and Lundbeck Foundation GeoGenetics Centre (Denmark) collaborated to generate one of the largest ancient genome datasets. This partnership will also help explore the relationship between the evolutionary history of select mental & neurological disorders and infectious pathogens.

The global metagenomic sequencing market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product & Service
  • 3.2. Market snippet by Technology
  • 3.3. Market snippet by Workflow
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Increasing initiatives and funding for large-scale sequencing projects
    • 4.2.2. Large applications of metagenomics in various fields
    • 4.2.3. XX
  • 4.3. Restraints
    • 4.3.1. Budget constraints in developing countries
    • 4.3.2. Lack of skilled professionals
    • 4.3.3. XX
  • 4.4. Opportunity
    • 4.4.1. Emerging cloud computing for data management
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Clinical Trials
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product & Service

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service Segment
  • 7.3. Market Attractiveness Index, By Product & Service Segment
    • 7.3.1. Instruments*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Reagents & Consumables
    • 7.3.3. Analyses & Data Interpretation Solutions
    • 7.3.4. Services
    • 7.3.5. Others

8. By Workflow

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 8.1.2. Market Attractiveness Index, By Workflow Segment
  • 8.2. Data Processing & Analysis *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Sample Processing & Library Preparation
  • 8.4. Sequencing

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
    • 9.1.2. Market Attractiveness Index, By Technology Segment
  • 9.2. Shotgun Metagenomic Sequencing*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. 16S rRNA Sequencing
  • 9.4. Whole Genome Sequencing & De Novo Assembly
  • 9.5. Metatranscriptomics

10. By Application

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 10.3. Market Attractiveness Index, By Application Segment
    • 10.3.1. Drug Discovery*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Clinical Diagnostics
    • 10.3.3. Veterinary Applications
    • 10.3.4. Ecological and Environmental Applications
    • 10.3.5. Industrial applications
    • 10.3.6. Soil Microbiome Applications
    • 10.3.7. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. The U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. The U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. The Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Qiagen N.V.
  • 13.3. BGI Group
  • 13.4. DNAstar, Inc.
  • 13.5. Eurofins Scientific
  • 13.6. Illumina, Inc.
  • 13.7. Macrogen, Inc.
  • 13.8. Oxford Nanopore Technologies Ltd.
  • 13.9. NuGEN Technologies, Inc. (A Wholly Owned Subsidiary of Tecan Trading AG)
  • 13.10. F. Hoffmann-La Roche Ltd.
  • 13.11. Perkinelmer, Inc.
  • 13.12. Integragen SA
  • 13.13. Microsynth AG
  • 13.14. Novogene Co., Ltd.
  • 13.15. Zymo Research Corporation (List Not Exhaustive)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us